CTI Clinical Trial and Consulting Services Announces Multiple Office Expansions
CTI Clinical Trial and Consulting Services
(CTI) announces the expansion of its offices in Cincinnati, Ohio (Global Headquarters); Raleigh, North Carolina; Madrid, Spain; and Ulm, Germany (European Headquarters).
“This reflects continued growth of the company due to new business awards from our current pharmaceutical and biotechnology sponsors,” according to Timothy J. Schroeder, CTI CEO and President. “We are very fortunate to have long term relationships with these sponsors, in some cases for more than a decade, and they continue to partner with us. We are extremely grateful for the opportunities.”
CTI currently works with more than 60 pharmaceutical and biotechnology companies, including eight of the ten largest global companies. These office expansions will allow for expanded capabilities and additional personnel across all departments.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
